SCHEMBL14014127

SCHEMBL14014127

Cc1ccc(NC(=O)Nc2cc(F)cc(C(F)(F)F)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.57
EPHX2 P34913 1/20 0.56
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
PSEN1 P49768 1/20 0.54
PSEN2 P49810 1/20 0.54
APH1B Q8WW43 1/20 0.54
NCSTN Q92542 1/20 0.54
APH1A Q96BI3 1/20 0.54
PSENEN Q9NZ42 1/20 0.54
MAPT P10636 5/20 0.54
HTT P42858 5/20 0.54
LMNA P02545 2/20 0.54
XBP1 P17861 2/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16786359 0.91 MAPT (0.65) MTOREPHX2MEN1KMT2ACA12
SCHEMBL16946637 0.82 EPHX2 (0.81) MTOREPHX2MEN1KMT2ACA12
SCHEMBL13875344 0.81 KMT2A (0.77) MTORMEN1KMT2AMAPTHTT
SCHEMBL28140770 0.79 MAPT (0.58) MTOREPHX2MEN1KMT2ACA12
SCHEMBL11001590 0.79 EPHX2 (0.81) MTOREPHX2MEN1KMT2ACA12
SCHEMBL3620508 0.79 GPR35 (0.58) MAPTLMNAP2RX1TMPRSS4
SCHEMBL17664318 0.79 EPHX2 (0.81) MTOREPHX2MEN1KMT2ACA12
SCHEMBL3275762 0.78 MAPT (0.60) MTOREPHX2MEN1KMT2ACA12
SCHEMBL3276644 0.78 KDR (0.74) MTORCA1CA2CA9KDR
SCHEMBL12144643 0.78 MAPT (0.54) MAPTLMNASMN1; SMN2P2RX1TMPRSS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MTOR 1029/4885EPHX2 736/4885MEN1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.